CREDIT HOURS
Pharmacist CPE: 2.0
Educational Gap and Need
According to the Centers for Disease Control and Prevention, approximately two million people develop bacterial infections in US hospitals each year, resulting in nearly 100,000 deaths. In 2004, the Infectious Diseases Society of America (IDSA) published the call-to-action “Bad Bugs, No Drugs” that highlighted the problem of antimicrobial resistance and the lack of new agents in development. This has since been updated to “Bad Bugs, No ESKAPE”, where the IDSA identified the most problematic pathogens that are able to “escape” the effects of currently available agents. These pathogens include methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii and Pseudomonas aeruginosa, and ESBL-producing and KPC-producing Enterobacteriaceae.
The lack of new antimicrobial agents limits the clinicians’ ability to effectively treat hospital-acquired infections caused by these difficult pathogens. Therefore, it is necessary to recognize the challenges associated with each type of infection and to know how to address these challenges in the clinical setting. Continued education can be an important strategy in achieving positive clinical outcomes by promoting the appropriate use of antimicrobial agents.
TARGET AUDIENCE
This activity has been designed to meet the needs of pharmacists who are responsible for the management of serious infections in hospitalized patients.
LEARNING OBJECTIVES
Those healthcare professionals participating in this application-based activity will be able at its conclusion to:
-
Identify the characteristics of key multidrug-resistant bacteria that cause hospital-acquired infections (HAIs).
-
Implement antimicrobial dosing based on pharmacokinetic and pharmacodynamic principles to reduce resistance development.
-
Proactively contribute as a key decision-maker in the management of patients with HAIs.
EDUCATIONAL FORMAT
This educational activity will incorporate debate-style presentations followed by impromptu discussions among the faculty. Three faculty members will provide arguments supporting why their pathogen (MRSA, Acinetobacter/Pseudomonas, or ESBL/KPC-producing Enterobacteriaceae) should be considered the “baddest” bug. Following each pro argument, a short rebuttal will describe how clinical pharmacists can help to address the challenges associated with infections caused by the particular pathogen. To support an interdisciplinary approach, a panel consisting of an infectious diseases physician and a microbiologist will comment on their perceived issues associated with each of these difficult pathogens. An audience response system will be utilized throughout the program to generate interactivity with the participants.
AGENDA
Registration and Dinner: 5:30 PM – 6:00 PM
Educational Program: 6:00 PM – 8:00 PM |
| 6:00 – 6:05 PM |
Welcome to the Debate
David P. Nicolau – Moderator
|
| 6:05 – 6:35 PM |
Why MRSA is the “Baddest Bug”
Pro Argument - David P. Nicolau
Rebuttal – Robert P. Rapp
Broader Perspectives – George G. Zhanel, Loren G. Miller
|
| 6:35 – 7:10 PM |
Why ESBL/KPC-producing Enterobacteriaceae are
the “Baddest Bugs”
Pro Argument – Robert P. Rapp
Rebuttal – Richard H. Drew
Broader Perspectives – George G. Zhanel, Loren G. Miller
|
| 7:10 – 7:45 PM |
Why Acinetobacter/Pseudomonas are the “Baddest Bugs”
Pro Argument – Richard H. Drew
Rebuttal – David P. Nicolau
Broader Perspectives – George G. Zhanel, Loren G. Miller
|
| 7:45 – 7:50 PM |
Closing Arguments
All faculty
Vote for the “Baddest Bug”
|
| 7:50 – 8:00 PM |
Interactive Q&A with the Faculty
|
FEE
There is no fee to participate in this educational activity.
ACCREDITATION
Pharmacists
 Massachusetts College of Pharmacy and Health Sciences (MCPHS) is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Participants will receive two (2.0) contact hours (0.2 CEUs) for this activity. No partial credit will be awarded.
UAN: 0026-9999-09-083-L01-P Activity type: Application-based
For questions regarding the accreditation of this activity, please contact MCPHS at Dawna.Burrus@mcphs.edu
INSTRUCTIONS FOR CREDIT
To receive a CE Statement of Credit, participants must register for the symposium, document attendance, and complete and return the evaluation form. A CE Statement of Credit will be mailed to you 4 weeks after the symposium.
DISCLOSURE OF CONFLICTS OF INTEREST
Massachusetts College of Pharmacy and Health Sciences and Vemco MedEd require faculty, planners, and others who are in a position to control the content of continuing education activities to disclose to the audience any real or apparent conflict of interest related to the activity. All identified conflicts of interest are reviewed to ensure fair balance, objectivity, and scientific rigor in all activities. The faculty is further required to disclose discussion of off-label uses in their presentations.
DISCLOSURES
Faculty
David P. Nicolau, PharmD, FCCP, FIDSA serves on the advisory boards and is a consultant for AstraZeneca, Cubist, Wyeth, Pfizer, Ortho-McNeil, and Merck. He receives grant/research support, has intellectual property/patents and serves on speakers bureaus for AstraZeneca, Ortho-McNeil, Cubist, Wyeth, Merck, and Pfizer.
Robert P. Rapp, PharmD, FCCP serves on the advisory boards for Wyeth, Ortho-McNeil, and Astellas. He serves on the speakers bureaus for Wyeth, Ortho-McNeil, and Astellas.
Richard H. Drew, PharmD, MS, BCPS serves on the advisory boards for Schering-Plough, Wyeth-Ayerst, and Astellas. He receives research support from Schering-Plough and Cubist. He serves on speakers bureaus for Schering-Plough, Wyeth-Ayerst, and Merck and is on the development Team for CustomID.
Loren G. Miller, MD, MPH is a consultant for Theravance and receives research/grant support from Pfizer and Cubist.
George G. Zhanel, PharmD, PhD serves on the advisory boards for Merck, Ortho-McNeil, and Wyeth. He receives research/grant support from Abbott, Affinium, Astellas, Wyeth, Pfizer, TaiGen, Ortho-McNeil, Bayer, Sepracor, and Advanced Life Sciences.
Planning Committee
Employees of Massachusetts College of Pharmacy and Health Sciences and Vemco MedEd have no relevant financial relationships to disclose.
AMERICANS WITH DISABILITIES ACT
Vemco MedEd and Massachusetts College of Pharmacy and Health Sciences fully comply with the Americans With Disabilities Act. Please submit a written request at least 5 days prior to the meeting, and we will be glad to assist you with any special needs required to make this program accessible to you. You may send a fax to the attention of Barbara Hassid at (908) 704-2424 or email your request to BaddestBug@vemcomeded.com.
Jointly sponsored by
Massachusetts College of Pharmacy and Health Sciences and Vemco MedEd
Supported by an educational grant from Ortho-McNeil, Inc., administered
by Ortho-McNeil Janssen Scientific Affairs, LLC
.
|
